However, Batf3 was also required to control tumour growth following routes that do not produce Trm, such as i.p. infection with rVACV-OVA and i.d. challenge with B16-OVA cells (Fig. 7f) or following i.p. infection with rVACV-OVA and i.v. challenge with B16-OVA cells (Fig. 7g). Here, BATF3 is linked to neoplasm.